JP2010512315A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010512315A5 JP2010512315A5 JP2009540288A JP2009540288A JP2010512315A5 JP 2010512315 A5 JP2010512315 A5 JP 2010512315A5 JP 2009540288 A JP2009540288 A JP 2009540288A JP 2009540288 A JP2009540288 A JP 2009540288A JP 2010512315 A5 JP2010512315 A5 JP 2010512315A5
- Authority
- JP
- Japan
- Prior art keywords
- ifnα
- inducible
- activity
- expression profile
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims 21
- 230000000694 effects Effects 0.000 claims 11
- 239000003550 marker Substances 0.000 claims 11
- 108090000623 proteins and genes Proteins 0.000 claims 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 208000035475 disorder Diseases 0.000 claims 8
- 210000004027 cell Anatomy 0.000 claims 5
- 239000000523 sample Substances 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 4
- 206010025135 lupus erythematosus Diseases 0.000 claims 4
- 102100027769 2'-5'-oligoadenylate synthase 1 Human genes 0.000 claims 3
- 102100035688 Guanylate-binding protein 1 Human genes 0.000 claims 3
- 101001008907 Homo sapiens 2'-5'-oligoadenylate synthase 1 Proteins 0.000 claims 3
- 101001001336 Homo sapiens Guanylate-binding protein 1 Proteins 0.000 claims 3
- 101001082070 Homo sapiens Interferon alpha-inducible protein 6 Proteins 0.000 claims 3
- 101000840293 Homo sapiens Interferon-induced protein 44 Proteins 0.000 claims 3
- 101000657037 Homo sapiens Radical S-adenosyl methionine domain-containing protein 2 Proteins 0.000 claims 3
- 101000880044 Homo sapiens SLIT-ROBO Rho GTPase-activating protein 3 Proteins 0.000 claims 3
- 101000822540 Homo sapiens Sterile alpha motif domain-containing protein 9-like Proteins 0.000 claims 3
- 101000814514 Homo sapiens XIAP-associated factor 1 Proteins 0.000 claims 3
- 102100027354 Interferon alpha-inducible protein 6 Human genes 0.000 claims 3
- 102100029607 Interferon-induced protein 44 Human genes 0.000 claims 3
- 102100033749 Radical S-adenosyl methionine domain-containing protein 2 Human genes 0.000 claims 3
- 102100037372 SLIT-ROBO Rho GTPase-activating protein 2 Human genes 0.000 claims 3
- 102100022459 Sterile alpha motif domain-containing protein 9-like Human genes 0.000 claims 3
- 102100039488 XIAP-associated factor 1 Human genes 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- 201000002481 Myositis Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 2
- 206010047115 Vasculitis Diseases 0.000 claims 2
- 208000033017 acquired idiopathic inflammatory myopathy Diseases 0.000 claims 2
- 239000003124 biologic agent Substances 0.000 claims 2
- 201000001981 dermatomyositis Diseases 0.000 claims 2
- 238000001514 detection method Methods 0.000 claims 2
- 208000013643 idiopathic inflammatory myopathy Diseases 0.000 claims 2
- 201000008319 inclusion body myositis Diseases 0.000 claims 2
- 208000005987 polymyositis Diseases 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 201000000306 sarcoidosis Diseases 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 108090000790 Enzymes Proteins 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 108020004999 messenger RNA Proteins 0.000 claims 1
- 108091033319 polynucleotide Proteins 0.000 claims 1
- 239000002157 polynucleotide Substances 0.000 claims 1
- 102000040430 polynucleotide Human genes 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 150000003384 small molecules Chemical group 0.000 claims 1
- 230000003827 upregulation Effects 0.000 claims 1
Applications Claiming Priority (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US87300806P | 2006-12-06 | 2006-12-06 | |
| US90776707P | 2007-04-16 | 2007-04-16 | |
| US90776207P | 2007-04-16 | 2007-04-16 | |
| US92422007P | 2007-05-03 | 2007-05-03 | |
| US92421907P | 2007-05-03 | 2007-05-03 | |
| US92458407P | 2007-05-21 | 2007-05-21 | |
| US96018707P | 2007-09-19 | 2007-09-19 | |
| US99617607P | 2007-11-05 | 2007-11-05 | |
| US99617407P | 2007-11-05 | 2007-11-05 | |
| US99621907P | 2007-11-06 | 2007-11-06 | |
| US99682007P | 2007-12-06 | 2007-12-06 | |
| PCT/US2007/024941 WO2008070135A2 (en) | 2006-12-06 | 2007-12-06 | Methods of treating systemic lupus erythematosus |
| PCT/US2007/024947 WO2008070137A2 (en) | 2006-12-06 | 2007-12-06 | Interferon alpha-induced pharmacodynamic markers |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013183939A Division JP2014014370A (ja) | 2006-12-06 | 2013-09-05 | インターフェロンα誘導性薬力学的マーカー |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010512315A JP2010512315A (ja) | 2010-04-22 |
| JP2010512315A5 true JP2010512315A5 (enExample) | 2011-01-20 |
Family
ID=39492862
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009540285A Pending JP2010512313A (ja) | 2006-12-06 | 2007-12-06 | 全身性エリテマトーデスの治療方法 |
| JP2009540288A Pending JP2010512315A (ja) | 2006-12-06 | 2007-12-06 | インターフェロンα誘導性薬力学的マーカー |
| JP2013183939A Pending JP2014014370A (ja) | 2006-12-06 | 2013-09-05 | インターフェロンα誘導性薬力学的マーカー |
| JP2013193959A Pending JP2014040430A (ja) | 2006-12-06 | 2013-09-19 | 全身性エリテマトーデスの治療方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009540285A Pending JP2010512313A (ja) | 2006-12-06 | 2007-12-06 | 全身性エリテマトーデスの治療方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013183939A Pending JP2014014370A (ja) | 2006-12-06 | 2013-09-05 | インターフェロンα誘導性薬力学的マーカー |
| JP2013193959A Pending JP2014040430A (ja) | 2006-12-06 | 2013-09-19 | 全身性エリテマトーデスの治療方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (5) | US20100143373A1 (enExample) |
| EP (3) | EP2712930A3 (enExample) |
| JP (4) | JP2010512313A (enExample) |
| KR (2) | KR20090088932A (enExample) |
| AU (2) | AU2007327993B2 (enExample) |
| BR (2) | BRPI0719912A2 (enExample) |
| CA (2) | CA2670897A1 (enExample) |
| MX (1) | MX2009005787A (enExample) |
| RU (2) | RU2527068C2 (enExample) |
| WO (2) | WO2008070135A2 (enExample) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008070135A2 (en) * | 2006-12-06 | 2008-06-12 | Medimmune, Llc. | Methods of treating systemic lupus erythematosus |
| CA2685147A1 (en) * | 2007-05-03 | 2008-11-13 | Medimmune, Llc | Auto-antibody markers of autoimmune disease |
| ES2542836T3 (es) * | 2007-07-12 | 2015-08-12 | The Brigham And Women's Hospital, Inc. | Composiciones y métodos para diagnosticar y evaluar miopatías inflamatorias |
| CN101909444B (zh) | 2007-11-05 | 2013-09-18 | 米迪缪尼有限公司 | 硬皮病治疗方法 |
| AU2009212216B2 (en) * | 2008-02-08 | 2015-04-09 | Brigham And Women's Hospital, Inc. | Disease markers and uses thereof |
| ES2613055T3 (es) * | 2009-09-03 | 2017-05-22 | Medimmune, Llc | Diagnóstico de interferón de tipo 1 |
| CN103237901B (zh) | 2010-03-01 | 2016-08-03 | 卡里斯生命科学瑞士控股有限责任公司 | 用于治疗诊断的生物标志物 |
| CA2795776A1 (en) | 2010-04-06 | 2011-10-13 | Caris Life Sciences Luxembourg Holdings, S.A.R.L. | Circulating biomarkers for disease |
| US9709565B2 (en) | 2010-04-21 | 2017-07-18 | Memed Diagnostics Ltd. | Signatures and determinants for distinguishing between a bacterial and viral infection and methods of use thereof |
| WO2012088305A1 (en) * | 2010-12-22 | 2012-06-28 | The Feinstein Institute For Medical Research | Methods for treating systemic lupus erythematosus using hiv protease inhibitors |
| AU2013204880B2 (en) * | 2011-04-26 | 2016-11-24 | Genentech, Inc. | Compositions and method for treating autoimmune diseases |
| CA2834203A1 (en) * | 2011-04-26 | 2012-11-01 | Genentech, Inc. | Compositions and method for treating autoimmune diseases |
| GB201115665D0 (en) * | 2011-09-09 | 2011-10-26 | Univ Leuven Kath | Autoimmune and inflammatory disorder therapy |
| MX339762B (es) | 2011-09-28 | 2016-05-27 | Univ Autonoma Del Estado De Morelos | Metalopeptidos inmunomoduladores (immp) y composiciones que los contienen. |
| WO2013101771A2 (en) | 2011-12-30 | 2013-07-04 | Genentech, Inc. | Compositions and method for treating autoimmune diseases |
| ES2886979T3 (es) | 2012-02-09 | 2021-12-21 | Memed Diagnostics Ltd | Distintivos y determinantes para diagnosticar infecciones y métodos para usarlos |
| WO2013173266A1 (en) | 2012-05-17 | 2013-11-21 | The Johns Hopkins University | Methods for identifying patterns of ifn induced expression and use in diagnosis, monitoring and therapy |
| US9493570B2 (en) * | 2012-06-13 | 2016-11-15 | Medimmune, Llc | Fixed dosage regimens for anti-type I interferon receptor (IFNAR) antibodies |
| US20140156297A1 (en) * | 2012-08-03 | 2014-06-05 | Axelacare Holdings, Inc. | Computer program, method, and system for pharmacist-assisted treatment of patients |
| US20140039907A1 (en) * | 2012-08-03 | 2014-02-06 | AxelaCare Health Solutions, Inc. | Computer program, method, and system for collecting patient data with a portable electronic device |
| US20140275257A1 (en) * | 2013-03-14 | 2014-09-18 | Foundation for the State University of New York | N-acetyl cysteine compositions in the treatment of systemic lupus erythematosus |
| EP3180621B1 (en) | 2014-08-14 | 2020-04-01 | Memed Diagnostics Ltd. | Computational analysis of biological data using manifold and a hyperplane |
| CN105420347A (zh) * | 2014-08-21 | 2016-03-23 | 南京大学医学院附属鼓楼医院 | 一种用于系统性红斑狼疮的基因诊断试剂盒 |
| WO2016059636A1 (en) | 2014-10-14 | 2016-04-21 | Memed Diagnostics Ltd. | Signatures and determinants for diagnosing infections in non-human subjects and methods of use thereof |
| CN111624345A (zh) | 2014-12-11 | 2020-09-04 | 米密德诊断学有限公司 | 用于诊断多种感染的标记组合及其使用方法 |
| IL287757B (en) | 2016-03-03 | 2022-07-01 | Memed Diagnostics Ltd | Analyzing rna for diagnosing infection type |
| CA3015046A1 (en) | 2016-03-03 | 2017-09-08 | Memed Diagnostics Ltd. | Rna determinants for distinguishing between bacterial and viral infections |
| CN109804245B (zh) | 2016-07-10 | 2022-10-25 | 米密德诊断学有限公司 | 感染的早期诊断 |
| EP4141448A1 (en) | 2016-07-10 | 2023-03-01 | MeMed Diagnostics Ltd. | Protein signatures for distinguishing between bacterial and viral infections |
| WO2018060999A1 (en) | 2016-09-29 | 2018-04-05 | Memed Diagnostics Ltd. | Methods of risk assessment and disease classification |
| WO2018060998A1 (en) | 2016-09-29 | 2018-04-05 | Memed Diagnostics Ltd. | Methods of prognosis and treatment |
| US20200008916A1 (en) * | 2016-12-16 | 2020-01-09 | The Penn State Research Foundation | Methods for improved reproductive management of ruminant ungulates |
| WO2018136625A2 (en) * | 2017-01-20 | 2018-07-26 | Children's Medical Center Corporation | Compositions and methods for treating diseases characterized by reactive microglia mediated synapse loss |
| US10209260B2 (en) | 2017-07-05 | 2019-02-19 | Memed Diagnostics Ltd. | Signatures and determinants for diagnosing infections and methods of use thereof |
| EP3658173A1 (en) | 2017-07-25 | 2020-06-03 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for modulating monocytopoiesis |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| EA202191133A1 (ru) | 2018-10-26 | 2021-07-12 | Янссен Байотек, Инк. | Сигнатуры интерферона типа i и способы их применения |
| JP7558167B2 (ja) | 2018-12-03 | 2024-09-30 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | オリゴベンズアミド類似体およびがん処置におけるそれらの使用 |
| KR20210131354A (ko) | 2019-02-15 | 2021-11-02 | 아스트라제네카 아베 | I형 인터페론-매개 장애 |
| US12011284B2 (en) * | 2020-05-19 | 2024-06-18 | Peachy Corp. | Systems and methods for preventing and treating wrinkles |
| KR102429261B1 (ko) | 2020-08-25 | 2022-08-03 | 충북대학교 산학협력단 | 한국인의 tnf 저해제 약물 반응성 예측을 위한 바이오마커 |
| JP2023544351A (ja) * | 2020-10-02 | 2023-10-23 | セルジーン コーポレーション | 全身性エリテマトーデスを治療する方法及び治療に対する臨床的感受性の予測因子としてのバイオマーカの使用 |
| LT4114465T (lt) | 2021-04-23 | 2023-11-10 | Astrazeneca Ab | Anti-ifnar1 dozavimo režimas, skirtas poodinei injekcijai |
| MX2023015230A (es) | 2021-06-18 | 2024-01-18 | Ionis Pharmaceuticals Inc | Compuestos y metodos para reducir la expresion de ifnar1. |
| FR3138815A1 (fr) * | 2022-08-12 | 2024-02-16 | bioMérieux | Détermination de la nature virale ou bactérienne d’une infection |
| CN117305441B (zh) * | 2023-10-13 | 2025-04-08 | 福建农林大学 | 一种2型糖尿病的生物标志物和治疗靶点及浒苔寡糖的应用方法 |
| WO2025213238A1 (en) * | 2024-04-12 | 2025-10-16 | HaemaLogiX Ltd | Anti-kma antibody formulations |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8303165D0 (en) | 1983-02-04 | 1983-03-09 | Secher D S | Monoclonal antibody |
| EP0139676B1 (en) | 1983-02-04 | 1992-11-25 | Cytoclonal Pharmaceutics Inc. | Production and characterization of hybridoma antibodies directed specifically against common determinant(s) present among closely related, but distinct proteins |
| DE3306060A1 (de) | 1983-02-22 | 1984-08-23 | Boehringer Ingelheim International GmbH, 6507 Ingelheim | Neue immunglobulin-produzierende hybridzellinien, deren verwendung und verfahren zu deren herstellung |
| EP0205404B1 (en) | 1985-06-11 | 1992-07-15 | Ciba-Geigy Ag | Hybrid interferons |
| US5744101A (en) | 1989-06-07 | 1998-04-28 | Affymax Technologies N.V. | Photolabile nucleoside protecting groups |
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| FR2692168B1 (fr) | 1992-06-16 | 1995-03-24 | Centre Nat Rech Scient | Préparation et utilisation de nouveaux systèmes colloïdaux dispersibles à base de cyclodextrine, sous forme de nanosphères. |
| US5888511A (en) * | 1993-02-26 | 1999-03-30 | Advanced Biotherapy Concepts, Inc. | Treatment of autoimmune diseases, including AIDS |
| US6077835A (en) | 1994-03-23 | 2000-06-20 | Case Western Reserve University | Delivery of compacted nucleic acid to cells |
| AU696455C (en) | 1994-03-23 | 2006-03-02 | Case Western Reserve University | Compacted nucleic acids and their delivery to cells |
| US5972901A (en) | 1994-03-23 | 1999-10-26 | Case Western Reserve University | Serpin enzyme complex receptor--mediated gene transfer |
| US6905587B2 (en) * | 1996-03-22 | 2005-06-14 | Ronald Redline | Method for enhancing the solderability of a surface |
| EP0989849A2 (en) | 1997-06-13 | 2000-04-05 | The Johns Hopkins University School Of Medicine | Therapeutic nanospheres |
| AU757961B2 (en) * | 1998-09-30 | 2003-03-13 | Sankyo Company Limited | Anti-Fas antibodies |
| US20050008683A1 (en) * | 2000-06-29 | 2005-01-13 | Becton Dickinson And Company | Method for delivering interferons to the intradermal compartment |
| US7087726B2 (en) * | 2001-02-22 | 2006-08-08 | Genentech, Inc. | Anti-interferon-α antibodies |
| US6905827B2 (en) * | 2001-06-08 | 2005-06-14 | Expression Diagnostics, Inc. | Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases |
| WO2003046008A1 (en) * | 2001-11-30 | 2003-06-05 | Innogenetics N.V. | Therapeutic use of antibodies and fragments thereof binding primate ifn-gamma |
| PT1569696E (pt) * | 2002-11-21 | 2010-11-11 | Bayhill Therapeutics Inc | Composições para prevenção e tratamento de esclerose múltipla e diabetes de tipo 1 |
| JP2007503838A (ja) * | 2003-09-05 | 2007-03-01 | ジーティーシー バイオセラピューティクス， インコーポレイティド | トランスジェニック動物の乳汁中での融合タンパク質の産生方法 |
| DK1711207T3 (da) * | 2003-12-10 | 2013-03-11 | Medarex Inc | Interferon-alpha-antistoffer og anvendelse heraf |
| EP1781705B1 (en) * | 2004-06-21 | 2014-10-08 | Medarex, L.L.C. | Interferon alpha receptor i antibodies and their uses |
| US20070166281A1 (en) * | 2004-08-21 | 2007-07-19 | Kosak Kenneth M | Chloroquine coupled antibodies and other proteins with methods for their synthesis |
| US7833795B2 (en) * | 2004-08-24 | 2010-11-16 | The Trustees Of The University Of Pennsylvania | Assessment of cardiovascular risk using isoprostane biomarkers and COX-2 selective inhibitors |
| US7571055B2 (en) * | 2004-10-13 | 2009-08-04 | Regents Of The University Of Minnesota | Systemic lupus erythematosus |
| CA2597265C (en) * | 2005-02-10 | 2015-03-24 | Baylor Research Institute | Anti-interferon alpha monoclonal antibodies and methods for use |
| WO2008021976A2 (en) * | 2006-08-09 | 2008-02-21 | Baylor Research Institute | Anti-interferon alpha monoclonal antibodies and methods for use |
| US20070117105A1 (en) * | 2005-05-12 | 2007-05-24 | Crow Mary K | Interferon assay |
| US20070065844A1 (en) * | 2005-06-08 | 2007-03-22 | Massachusetts Institute Of Technology | Solution-based methods for RNA expression profiling |
| EP1945800B1 (en) * | 2005-08-05 | 2012-03-14 | Genentech, Inc. | Methods and compositions for detecting autoimmune disorders |
| US7608395B2 (en) * | 2005-09-15 | 2009-10-27 | Baylor Research Institute | Systemic lupus erythematosus diagnostic assay |
| EA015860B1 (ru) * | 2005-10-13 | 2011-12-30 | Хьюман Дженом Сайенсиз, Инк. | Способы лечения аутоиммунных заболеваний при использовании антагониста нейтрокина-альфа |
| WO2008070135A2 (en) * | 2006-12-06 | 2008-06-12 | Medimmune, Llc. | Methods of treating systemic lupus erythematosus |
| AU2008232903B9 (en) * | 2007-03-30 | 2013-09-05 | Medimmune Llc | Antibodies with decreased deamidation profiles |
| ES2613055T3 (es) * | 2009-09-03 | 2017-05-22 | Medimmune, Llc | Diagnóstico de interferón de tipo 1 |
-
2007
- 2007-12-06 WO PCT/US2007/024941 patent/WO2008070135A2/en not_active Ceased
- 2007-12-06 US US12/517,334 patent/US20100143373A1/en not_active Abandoned
- 2007-12-06 EP EP13179923.1A patent/EP2712930A3/en not_active Withdrawn
- 2007-12-06 AU AU2007327993A patent/AU2007327993B2/en not_active Ceased
- 2007-12-06 JP JP2009540285A patent/JP2010512313A/ja active Pending
- 2007-12-06 KR KR1020097013891A patent/KR20090088932A/ko not_active Ceased
- 2007-12-06 EP EP07867634A patent/EP2073844A4/en not_active Ceased
- 2007-12-06 JP JP2009540288A patent/JP2010512315A/ja active Pending
- 2007-12-06 KR KR1020097013872A patent/KR101532797B1/ko not_active Expired - Fee Related
- 2007-12-06 CA CA002670897A patent/CA2670897A1/en not_active Abandoned
- 2007-12-06 RU RU2009125616/10A patent/RU2527068C2/ru not_active IP Right Cessation
- 2007-12-06 BR BRPI0719912-0A2A patent/BRPI0719912A2/pt not_active IP Right Cessation
- 2007-12-06 US US12/517,333 patent/US20100143372A1/en not_active Abandoned
- 2007-12-06 CA CA002670594A patent/CA2670594A1/en not_active Abandoned
- 2007-12-06 EP EP07867637A patent/EP2077858A4/en not_active Ceased
- 2007-12-06 MX MX2009005787A patent/MX2009005787A/es active IP Right Grant
- 2007-12-06 AU AU2007327995A patent/AU2007327995B2/en not_active Ceased
- 2007-12-06 WO PCT/US2007/024947 patent/WO2008070137A2/en not_active Ceased
- 2007-12-06 BR BRPI0720035-8A patent/BRPI0720035A2/pt active Search and Examination
-
2013
- 2013-09-05 JP JP2013183939A patent/JP2014014370A/ja active Pending
- 2013-09-19 JP JP2013193959A patent/JP2014040430A/ja active Pending
-
2014
- 2014-07-03 RU RU2014127178A patent/RU2014127178A/ru not_active Application Discontinuation
- 2014-07-14 US US14/330,609 patent/US20150044222A1/en not_active Abandoned
-
2015
- 2015-01-27 US US14/606,832 patent/US20150147336A1/en not_active Abandoned
-
2016
- 2016-10-11 US US15/290,925 patent/US20170121771A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010512315A5 (enExample) | ||
| JP2010527917A5 (enExample) | ||
| Magen et al. | Circulating miR-181 is a prognostic biomarker for amyotrophic lateral sclerosis | |
| Powell et al. | Tumor necrosis factor and its targets in the inflammatory cytokine pathway are identified as putative transcriptomic biomarkers for escitalopram response | |
| Aro et al. | Saliva liquid biopsy for point-of-care applications | |
| CN108138222B (zh) | 表观遗传染色体相互作用 | |
| Sypabekova et al. | Electrochemical aptasensor using optimized surface chemistry for the detection of Mycobacterium tuberculosis secreted protein MPT64 in human serum | |
| RU2014127178A (ru) | Фармакодинамические маркеры, индуцированные интерфероном альфа2009125616 06.12.2006 | |
| RU2010144502A (ru) | Композиции и способы для лечения и диагностики астмы | |
| NZ590988A (en) | Biomarkers for anti-tnf treatment in ulcerative colitis and related disorders | |
| TW201514310A (zh) | 發炎性疾病之抗－ｔｎｆ與抗－ｉｌ１７組合療法生物標記 | |
| JP2013526845A (ja) | サイトカイン標的薬（ＣｙＴＤ）に対する、炎症性疾患に罹患している対象の初期応答または非応答を予測する遺伝子および遺伝子の組み合わせ | |
| Lu et al. | Cancer bioinformatics for updating anticancer drug developments and personalized therapeutics | |
| US9580752B2 (en) | Methods of predicting medically refractive ulcerative colitis (MR-UC) requiring colectomy | |
| WO2007124309A3 (en) | Methods for detecting mutations in jak2 nucleic acid | |
| Liu et al. | Functional effect of polymorphisms in the promoter of TNFAIP3 (A20) in acute pancreatitis in the Han Chinese population | |
| Backes et al. | Influence of next-generation sequencing and storage conditions on miRNA patterns generated from PAXgene blood | |
| Hussain et al. | CCL2/MCP-I genotype-phenotype relationship in latent tuberculosis infection | |
| CN103820545B (zh) | 用于检测人abcg2基因突变的探针、引物及试剂盒 | |
| CN104120172B (zh) | 精神分裂症的基因标志物及其使用方法和应用 | |
| Angata et al. | Association of serum interleukin‐27 with the exacerbation of chronic obstructive pulmonary disease | |
| CN102787161A (zh) | 一种检测结核分枝杆菌方法及其专用引物 | |
| Moraes Holst et al. | Downregulated mucosal autophagy, alpha kinase-1 and IL-17 signaling pathways in active and quiescent ulcerative colitis | |
| Russell et al. | Host gene expression changes in cattle infected with Alcelaphine herpesvirus 1 | |
| Troudet et al. | Gene expression and response prediction to amisulpride in the OPTiMiSE first episode psychoses |